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Abstract Study of oxyhemoglobin in red blood cells and spleen tissues from normal
human and patient with primary myelofibrosis was carried out using Mössbauer
spectroscopy with a high velocity resolution. The 57Fe hyperfine parameters were
evaluated and small variations in quadrupole splitting were revealed for both normal
human and patient’s oxyhemoglobin and both normal human and patient’s spleen.
Keywords Mössbauer spectroscopy with a high velocity resolution · Quadrupole
splitting · Oxyhemoglobin · Spleen · Primary myelofibrosis
1 Introduction
Study of iron containing biomolecules in hematological malignances is of interest for
analysis of molecular nature of diseases. Previous studies of oxyhemoglobin (HbO2)
from patients with blood system malignant diseases [1–3] and spleen tissue (spleen
contains iron storage protein ferritin mainly) from leukemia chicken [4] showed
small variations of the 57Fe hyperfine parameters in comparison with those for
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normal human HbO2 and normal chicken spleen tissue, respectively. An increase
in velocity resolution in Mössbauer spectroscopy permits to achieve better adjusting
to resonance, more precise spectra measurement with decrease in instrumental error
on velocity scale and better fit of complicated spectra due to increase in spectral
points number (see [5–9]). New studies of normal HbO2 with different molecular
structure and HbO2 from patients with blood system malignant diseases as well
as chicken liver and spleen tissues with increased velocity resolution demonstrated
some small differences in the 57Fe hyperfine parameters [8, 10–12]. To continue these
studies we chose a case with a very rare blood system malignant disease named pri-
mary myelofibrosis (PMF). PMF is a myeloproliferative neoplasm characterized by
stem cell-derived clonal myeloproliferation, reactive bone marrow fibrosis, anemia,
splenomegaly, etc. [13]. We studied HbO2 in red blood cells (RBC) and spleen tissue
from patient with PMF in comparison with normal human HbO2 and spleen tissue
using Mössbauer spectroscopy with a high velocity resolution.
2 Experimental
Samples of human normal and patient’s spleen tissues and patient’s red blood cells
were obtained at the Hematological Division of the Sverdlovsk Regional Clinical
Hospital No 1 (Ekaterinburg). The diagnosis and classification of PMF was made
according to the World Health Organization criteria [13]. The spleen samples
were obtained from a patient with primary myelofibrosis with myeloid metaplasia
after splenectomy and a healthy man after traumatic spleen lesion. Spleen samples
were washed from blood using physiological solution then lyophilized. For further
investigations lyophilized spleen samples were powdered. Concentrated patient’s
RBC were obtaining by twice washing of venous fresh blood with physiological
solution and then oxygenated. Concentrated normal human RBC were obtained
from Hematological Research Center (Moscow) and oxygenated. The samples of
oxygenated RBC were immediately frozen in liquid nitrogen. The sample thickness
was about 0.9 mg Fe/cm2. Samples of lyophilized spleen contained 1200–1800 mg of
powder.
Mössbauer spectra were measured using an automated precision Mössbauer
spectrometric system built on the base of the SM-2201 spectrometer with a saw-tooth
shape velocity reference signal formed using 4096 bits. Details and characteristics
of this spectrometer and the system were given elsewhere [9, 14, 15]. The 1.8 ×
109 Bq 57Co in rhodium matrix (Ritverc GmbH, St. Petersburg) was used at room
temperature. The Mössbauer spectra were measured in transmission geometry with
moving absorber in the cryostat at 295 K (spleen) and 90 K (RBC and spleen) and
recorded in 4096 channels. For their analysis, the spectra of spleen and RBC samples
were converted into 1024 channels by a consequent summation of four neighboring
channels. Statistical count rate in the normal spleen spectrum was 6.4 × 106 counts
per channel with a signal-to-noise ratio of 8 while that for patient’s spleen spectra
were 5.7 × 105 counts per channel with a signal-to-noise ratio of 22 at 295 K and
3.7 × 106 counts per channel with a signal-to-noise ratio of 58 at 90 K (spectra
were measured up to four weeks). Statistical count rates in the spectra of HbO2
in RBC were ∼1.3 × 106 counts per channel for normal sample and ∼2.9 × 106
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Fig. 1 Mössbauer spectra of oxyhemoglobin in normal human red blood cells (a) and in red blood
cells from patient with primary myelofibrosis (b) measured at 90 K and presented in 1024 channels.
Indicated components are the results of the better fits within the second model (1—57Fe in α-
subunits, 2—57Fe in β-subunits, 3—probably carboxyhemoglobin)
counts per channel and the signal-to-noise ratio 17 and 20, respectively (spectra were
measured up to two weeks). The spectra were computer fitted with the least squares
procedure using UNIVEM-MS program with a Lorentzian line shape. The spectral
parameters such as: isomer shift, δ, quadrupole splitting, EQ, line width, , relative
subspectrum area, S, and statistical criterion, χ2, were determined. An instrumental
(systematic) error for each spectrum point was ±0.5 channel (the velocity scale),
the instrumental (systematic) error for the hyperfine parameters was ±1 channel.
If an error calculated with the fitting procedure (fitting error) for these parameters
exceeded the instrumental (systematic) error we used the larger error instead. Values
of δ are given relative to α–Fe at 295 K.
3 Results and discussion
Mössbauer spectra of HbO2 in human normal and patient’s RBC are shown in
Fig. 1. These spectra look like usual HbO2 spectra consisting of two main peaks with
asymmetry of the absorption line shapes [16].
These spectra were fitted using two models (see [10–12, 17]): 1) equivalent Fe(II)
electron structure in α- and β-subunits of HbO2 with spectra fitting using one
quadrupole doublet; 2) non-equivalent Fe(II) electron structure in α- and β-subunits
of HbO2 with spectra fitting using two quadrupole doublets with equal areas. It
should be noted that in the spectrum of normal human RBC an additional minor
component 3 (S ∼ 5 %) with parameters similar to carboxyhemoglobin (HbCO)
was observed. The values of  for the Mössbauer spectra of HbO2 from normal
human and patient with PMF obtained from the first model fit were 0.418 ± 0.012
and 0.361 ± 0.010 mm/s, respectively, and those obtained from the second model
were for α-subunits: 0.284 ± 0.012 and 0.233 ± 0.010 mm/s, and for β-subunits:
0.474 ± 0.012 and 0.369 ± 0.018 mm/s, for HbO2 from normal human and patient
with PMF, respectively. Details of these parameters analysis and relation to α- and
β-subunits of HbO2 were given in [17]. The values of δ and EQ obtained for HbO2
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Fig. 2 Mössbauer hyperfine parameters for oxyhemoglobins from normal human () and patient
with primary myelofibrosis () obtained from the spectra fit using model 1 (a) and model 2 for
α-subunits (b) and β-subunits (c)
a b c 
Fig. 3 Mössbauer spectra of normal human spleen (a) and spleen from patient with primary
myelofibrosis (b, c) measured at 295 K (a, b) and 90 K (c) and presented in 1024 channels. Indicated
components are the results of the better fits within the second model (component 3 (a, c) and
component 4 (b) is related to residual hemoglobin in the oxidized form, other components are related
to iron storage proteins)
using two models are shown in the plots of hyperfine parameters (Fig. 2). These
results demonstrated some differences in the 57Fe hyperfine parameters for normal
and patient’s HbO2.
Mössbauer spectra of normal human spleen and spleen from patient with PMF
measured at room temperature are shown in Fig. 3a,b. These spectra look like
paramagnetic spectra of iron storage proteins with residual amount of oxidized
hemoglobin (components 3 in Fig. 3a and 4 in Fig. 3b). These spectra were fitted
using two models (see [18, 19]): 1) homogeneous iron core in iron storage proteins
with spectra fitting using one quadrupole doublet; 2) heterogeneous iron core in
iron storage proteins with spectra fitting using several quadrupole doublets. Using
the fit within the first model it was possible to distinguish data for human normal
spleen and spleen from patient with PMF in the plot of δ and EQ values (Fig. 4).
The values of  for the Mössbauer spectra of spleen from normal human and
patient with PMF obtained from the first model fit were 0.418 ± 0.018 and 0.412 ±
0.010 mm/s, respectively. Unfortunately, it was not possible to compare the results
of these spectra fit using the second model due to a very small signal-to-noise
ratio for the spectrum of human normal spleen. It was shown in [18] that it takes
to reach a good signal-to-noise ratio in Mössbauer spectrum to use the second
model well. Nevertheless, it was interesting to observe significant increase in the
absorption effect in the Mössbauer spectrum of patient’s spleen. Assuming the iron
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Fig. 4 Mössbauer hyperfine
parameters for spleen from
normal human () and patient
with primary myelofibrosis
() obtained from the spectra
fit using model 1
overload in patient’s spleen Mössbauer spectrum of this sample was additionally
measured at 90 K (Fig. 3c). It is well known that in the case of the iron overload
due to β-thalassemia an additional magnetic sextet was observed at 77 K in patients’
spleen samples [20]. However, there was no magnetic component in the Mössbauer
spectrum of spleen from patient with PMF at 90 K (it should be noted that in the
case of the fit of this spectrum using additional minor sextet the obtained value of
δ for this component was ∼0.1 mm/s while the values of δ for both magnetic and
paramagnetic components in the Mössbauer spectra of iron storage proteins should
not be smaller than 0.4 mm/s at 90 K).
4 Conclusion
Study of oxyhemoglobin in red blood cells and spleen tissues from normal human
and patient with primary myelofibrosis using Mössbauer spectroscopy with a high
velocity resolution demonstrated some small variations in quadrupole splitting of
studied samples indicating small structural differences in correspondent biomacro-
molecules in normal human and patient. On the basis of differences in the absorption
effect it is possible to suppose a decrease in hemoglobin content in patient’s red
blood cells correlated with anemia in this disease and iron overload in spleen
correlated with splenomegaly, increased red blood cells lysis with heme iron release
and extramedullary hematopoiesis in patient’s spleen.
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